

European Heart Journal

Volume 43 No. 16 April 2022

ISSUE @ A GLANCE



Inflammation, targeted proteomics, and microvascular dysfunction: the new frontiers of ischaemic heart disease

F. Crea

1517

CardioPulse

Reaching the stars

M. Nicholls

1521

Opening a new window on cardiovascular research

M. Nicholls

1524

Cardiology Update India 21: a growing Indo-European educational platform to fight cardiovascular disease

V. Ram, R. Amstein, and T.F. Lüscher

1528

Weekly Journal Scan

In vivo generated chimeric antigen receptor T cells reduce fibrosis and restore cardiac function in experimental heart failure

G. Liuzzo and C. Patrono

1531

FOCUS ISSUE ON ISCHAEMIC HEART DISEASE

STATE OF THE ART REVIEW

Immune cells in cardiac homeostasis and disease: emerging insights from novel technologies

S. Steffens, M. Nahrendorf, and R. Madonna

1533

Management of acute coronary syndromes in older adults

N. Morici, S. De Servi, L. De Luca, G. Crimi, C. Montalto, R. De Rosa, G. De Luca, A. Rubboli, M. Valgimigli, and S. Savonitto

1542

CLINICAL RESEARCH



Alirocumab after acute coronary syndrome in patients with a history of heart failure

H.D. White, G.G. Schwartz, M. Szarek, D.L. Bhatt, V.A. Bittner, C.-E. Chiang, R. Diaz, S.G. Goodman, J.W. Jukema, M. Loy, N. Pagidipati, R. Pordy, A.D. Ristić, A.M. Zeiher, D.M. Wojdyla, and P.G. Steg for the ODYSSEY OUTCOMES Investigators

1554

Editorial

PCSK9 inhibition in patients with heart failure: neutral or harmful intervention?

A. Niessner and H. Drexel

1566



Targeted proteomics improves cardiovascular risk prediction in secondary prevention?

N.S. Nurmohamed, J.P. Belo Pereira, R.M. Hoogeveen, J. Kroon, J.M. Kraaijenhof, F. Waissi, N. Timmerman, M.J. Bom, I.E. Hoefer, P. Knaapen, A.L. Catapano, W. Koenig, D. de Kleijn, F.L.J. Visseren, E. Levin, and E.S.G. Stroes on behalf of the UCC-SMART Study Group

1569

Editorial

Proteomics for the prediction and prevention of atherosclerotic disease

P.M. Ridker

1578



META-ANALYSIS

3 Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis

M.A. Kelshiker, H. Seligman, J.P. Howard, H. Rahman, M. Foley, A.N. Nowbar, C.A. Rajkumar, M.J. Shun-Shin, Y. Ahmad, S. Sen, R. Al-Lamee, and R. Petraco on behalf of the Coronary Flow Outcomes reviewing committee

1582

Editorial

Coronary flow reserve: a versatile tool for interrogating pathophysiology, and a reliable marker of cardiovascular outcomes and mortality

V.R. Taqueti

1594

CARDIOVASCULAR FLASHLIGHT

Reduction of lipoprotein(a) with proprotein convertase subtilisin/kexin type 9 inhibitor as a potential contributor to modulating coronary inflammatory activity: insights from serial pericoronary adipose tissue analysis

S. Kitahara, Y. Kataoka, H. Miura, and T. Noguchi

1597

Cerebral protection device out of transcatheter heart procedures: a bridge to surgery

S. Calcagno, R. Di Pietro, G. Biondi-Zocca, and F. Versaci

1598

Massive biventricular thrombosis after transfemoral transcatheter aortic valve implantation

M.I. Dregosesc, M. Istrate, I. Sandu, and A.C. Iancu

1599

CORRIGENDUM

Corrigendum to: PCSK9 inhibition in patients with heart failure – neutral or harmful intervention?

1568

Corrigendum to: Proteomics for the prediction and prevention of atherosclerotic disease

1581

This paper is Editor's Choice and is available free online at <https://academic.oup.com/eurheartj>

Editor's choice

Open Access Paper

For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



www.eurheartj.org